Every 8-K that Palatin Technologies, Inc. (PTN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTN filings page.
Palatin Technologies, Inc. held its annual meeting of stockholders on July 28, 2026, where four proposals were presented: election of directors, ratification of the independent registered public accounting firm for the fiscal year ending June 30, 2026, an amendment to the 2011 Stock Incentive Plan to increase shares available for equity awards by 260,000 shares, and an advisory vote on executive compensation for the fiscal year ended June 30, 2025.
As of the June 22, 2026 record date, there were 1,842,625 votes entitled to be cast, including 1,779,275 common shares, 4,030 shares of Series A Preferred Stock (1,534 votes), and 3,400 shares of Series D Preferred Stock (61,816 votes). A total of 1,000,506 votes, or 54.3% of votes entitled, were present in person or by proxy. Director nominees received between 337,172 and 654,056 votes for, with 319,687 broker non-votes each. The auditor ratification proposal received 982,584 for, 15,833 against, and 2,089 abstentions; the stock plan amendment received 650,452 for, 28,736 against, 1,630 abstentions, and 319,687 broker non-votes; and the say-on-pay proposal received 649,559 for, 28,732 against, 2,527 abstentions, and 319,687 broker non-votes.
Palatin Technologies, Inc. plans to move its common stock listing from the NYSE American to the Nasdaq Capital Market. Trading on the NYSE American is expected to end on May 28, 2026, with Nasdaq trading beginning May 29, 2026, under the same symbol “PTN.”
The company develops melanocortin receptor–targeted therapies, including selective MC4R-based obesity programs for rare disorders such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. A once-weekly injectable MC4R agonist is targeted for an IND submission in the fourth quarter of 2026, and an oral MC4R agonist candidate is targeted for IND submission in the first half of 2027.
Palatin Technologies, Inc. filed an amended current report to update the outcome of a governance-related item from its 2025 annual stockholder meeting. Stockholders voted, on an advisory and non-binding basis, to hold future advisory votes on executive compensation every year, consistent with the Board of Directors’ recommendation.
In response, the Board has decided to include an annual advisory vote on the compensation of the company’s named executive officers in its proxy materials each year, until the next required stockholder vote on how often these advisory votes should occur.
Palatin Technologies, Inc. reports that NYSE American has determined its common stock is no longer suitable for listing under Section 1003(f)(v) of the NYSE American Company Guide because of the stock’s low selling price, and NYSE American has commenced delisting proceedings. Trading of the common stock on NYSE American was suspended on May 7, 2025. The common stock has traded on the OTCQB Market of the OTC Markets Group, initially under the symbol “PTNT”, then under “PTNTD” beginning August 12, 2025, for a twenty trading day period following a 1-for-50 reverse stock split. Effective September 10, 2025, the common stock again trades on the OTCQB Market under the symbol “PTNT”.
Palatin Technologies, Inc. entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim International GmbH to develop melanocortin receptor-targeted peptides for retinal diseases, including diabetic retinopathy. Palatin will assign certain patent rights, collaborate on research at Boehringer Ingelheim’s expense for two years (with a possible six‑month extension), and is entitled to an upfront payment of €2.0 million ($2.3 million), up to €18.0 million ($20.9 million) in near‑term research milestones, and up to €260 million ($301.6 million) in development, regulatory and commercial milestones, plus tiered sales royalties subject to specified reductions. The agreement runs on a product‑by‑product, country‑by‑country basis through the applicable royalty term, with termination rights for bankruptcy or material breach and with Boehringer Ingelheim also able to terminate for any reason after a notice period. Separately, Palatin’s common stock was determined no longer suitable for listing on NYSE American due to its low selling price and now trades on OTC Markets under the symbol PTNTD.
Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split approved by shareholders and the board, expected to become effective after market on August 11, 2025, with shares trading on a split-adjusted basis on the OTCQB at market open on August 12, 2025. The company was previously determined not suitable for NYSE American listing due to a low selling price; trading was suspended May 7, 2025, and the stock has since traded on OTC Pink and then OTCQB under the symbol PTNT. The timing change reflects a delayed FINRA approval now expected after market on August 11, 2025.
Palatin Technologies completed a 1-for-50 reverse stock split approved by shareholders, effective August 8, 2025 at 5:00 p.m. ET. The action combines every 50 shares into one share while leaving the par value and other terms unchanged. Shares are expected to trade on the OTCQB on a split-adjusted basis beginning August 11, 2025 and will use the temporary ticker PTNTD for 20 trading days.
The company disclosed that NYSE American determined the common stock was no longer suitable for listing due to a low selling price and commenced delisting proceedings, with trading suspended on May 7, 2025. The stock traded on the Pink Market May 8–June 6, 2025 and has traded on the OTCQB since June 9, 2025. Fractional shares will be paid in cash based on the five-day average closing price prior to August 8, 2025.